Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2008 May 17

PMID 18482025

Citations 30

Authors

Richard P Shank

Bruce E Maryanoff

Affiliations

Soon will be listed here.

Abstract

Topiramate (TPM; TOPAMAX) is a broad-spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D-fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.

Citing Articles

In silico drug repurposing at the cytoplasmic surface of human aquaporin 1.

Lloyd A, Austin-Muttitt K, Mullins J PLoS One. 2025; 20(1):e0314151.

PMID: 39787482 PMC: 11717375. DOI: 10.1371/journal.pone.0314151.

Protective Effect of Topiramate against Diabetic Retinopathy and Computational Approach Recognizing the Role of NLRP3/IL-1β/TNF-α Signaling.

Mohammad H, Eladl M, AbdelMaogood A, Elshaer R, Ghanam W, Elaskary A Biomedicines. 2023; 11(12).

PMID: 38137423 PMC: 10741203. DOI: 10.3390/biomedicines11123202.

Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians.

Coe C, Patel A, Lawrence D Clin Liver Dis (Hoboken). 2023; 21(5):125-129.

PMID: 37936927 PMC: 10627592. DOI: 10.1097/CLD.0000000000000033.

The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.

Moghaddam Sadegh A, Nazarinasab M, Behrouzian F, Rostami H, Mehrabi M Iran J Psychiatry. 2023; 18(4):371-379.

PMID: 37881418 PMC: 10594000. DOI: 10.18502/ijps.v18i4.13624.

Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations.

Pearl N, Babin C, Catalano N, Blake J, Ahmadzadeh S, Shekoohi S Adv Ther. 2023; 40(9):3626-3638.

PMID: 37368102 DOI: 10.1007/s12325-023-02586-y.

References

Monzani E, Shtil A, La Porta C . The water channels, new druggable targets to combat cancer cell survival, invasiveness and metastasis. Curr Drug Targets. 2007; 8(10):1132-7. DOI: 10.2174/138945007782151342. View

Cha B, Silveira D, Liu X, Hu Y, Holmes G . Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res. 2002; 51(3):217-32. DOI: 10.1016/s0920-1211(02)00157-2. View

Ben-Zeev B, Watemberg N, Augarten A, Brand N, Yahav Y, Efrati O . Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol. 2003; 18(4):254-7. DOI: 10.1177/08830738030180041001. View

Stringer J . A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. 2000; 40(2-3):147-53. DOI: 10.1016/s0920-1211(00)00118-2. View

Tekin A, Tekgul S, Atsu N, Bakkaloglu M, Kendi S . Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. J Urol. 2002; 168(6):2572-4. DOI: 10.1016/S0022-5347(05)64218-8. View

Vila Ceren C, Demestre Guasch X, Raspall Torrent F, Saco M, Sala Castellvi P, Martinez Nadal S . [Topiramate and pregnancy. Neonate with bone anomalies]. An Pediatr (Barc). 2005; 63(4):363-5. DOI: 10.1157/13079819. View

Picard F, Deshaies Y, Lalonde J, Samson P, Richard D . Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2001; 8(9):656-63. DOI: 10.1038/oby.2000.84. View

Russo E, Constanti A . Topiramate hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro. Br J Pharmacol. 2003; 141(2):285-301. PMC: 1574203. DOI: 10.1038/sj.bjp.0705617. View

Frima N, Grunewald R . A double-blind, placebo-controlled, crossover trial of topiramate in essential tremor. Clin Neuropharmacol. 2006; 29(2):94-6. DOI: 10.1097/00002826-200603000-00007. View

10.

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

11.

Gatto E, Uribe Roca M, Raina G, Micheli F . Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol. 2003; 26(6):294-6. DOI: 10.1097/00002826-200311000-00006. View

12.

MILLICHAP J, Woodbury D, Goodman L . Mechanism of the anticonvulsant action of acetazoleamide, a carbonic anhydrase inhibitor. J Pharmacol Exp Ther. 1955; 115(3):251-8. View

13.

Kline K, Carroll D, Malnar K . Painful diabetic peripheral neuropathy relieved with use of oral topiramate. South Med J. 2003; 96(6):602-5. DOI: 10.1097/01.SMJ.0000060886.57804.2E. View

14.

Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L . Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007; 9(3):360-8. DOI: 10.1111/j.1463-1326.2006.00618.x. View

15.

Glauser T, Dlugos D, Dodson W, Grinspan A, Wang S, Wu S . Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol. 2007; 22(6):693-9. DOI: 10.1177/0883073807303997. View

16.

Suchomelova L, Baldwin R, Kubova H, Thompson K, Sankar R, Wasterlain C . Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. Pediatr Res. 2006; 59(2):237-43. DOI: 10.1203/01.pdr.0000196333.16608.30. View

17.

Khan S, Liberzon I . Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD. Psychopharmacology (Berl). 2003; 172(2):225-9. DOI: 10.1007/s00213-003-1634-4. View

18.

Shank R, GARDOCKI J, Streeter A, Maryanoff B . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000; 41(S1):3-9. View

19.

Cudkowicz M, Shefner J, Schoenfeld D, Brown Jr R, Johnson H, Qureshi M . A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003; 61(4):456-64. DOI: 10.1212/wnl.61.4.456. View

20.

Garnett W . Clinical pharmacology of topiramate: a review. Epilepsia. 2000; 41(S1):61-5. DOI: 10.1111/j.1528-1157.2000.tb02174.x. View